Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403740 | 0.79 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL457162 | 0.74 | NOS3 (0.33) | — | |
| SCHEMBL27560371 | 0.72 | — | — | |
| SCHEMBL28026198 | 0.69 | ERBB2 (0.32) | — | |
| SCHEMBL892872 | 0.69 | CA1 (0.48) | KDM4EALDH1A1HPGDHSD17B10GABRA1 | |
| SCHEMBL28968602 | 0.69 | KDM4E (0.37) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL95192 | 0.69 | HRH3 (0.40) | KDM4EALDH1A1 | |
| SCHEMBL357603 | 0.69 | GABRA1 (0.48) | KDM4EALDH1A1HPGDHSD17B10GABRA1 | |
| SCHEMBL1403629 | 0.69 | HPGD (0.35) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL320244 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | claimed |
| JP-2011524906-A | — | — | 2011-09-08 | — | — | JP | claimed |
| EP-2306994-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | Amgen, Inc (US) | 2011-04-13 | — | — | EP | claimed |
| US-7842685-B2 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-11-30 | — | — | US | claimed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | claimed |
| WO-2009154775-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | claimed |
| EP-2046714-B1 | Cyclopentane derivatives as antiglaucoma agents | ALLERGAN INC (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2043993-B1 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN INC (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2069295-B1 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8569349-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2291353-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS USED AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN INC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2008008700-A2 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008701-A2 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2008008660-A2 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007149829-A2 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | PTGIR, PTGIS, PTGER2 | KDM4E 2886/4885ALDH1A1 883/4885HPGD 49/4885 |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | S1PR1, S1PR5, S1PR2 | KDM4E 2878/4885ALDH1A1 1637/4885HPGD 2237/4885 |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | THPO, HLA-C, PIGO | KDM4E 4700/4885ALDH1A1 1004/4885HPGD 1050/4885 |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | PTGER2, PTGER1, PTGS2 | KDM4E 3080/4885ALDH1A1 655/4885HPGD 16/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | KDM4E 4067/4885ALDH1A1 438/4885HPGD 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.